Should You Hold STERIS Stock in Your Portfolio Right Now?

Despite strong operational performance in Q1 fiscal 2026, with its Healthcare segment revenue growing 8% and Applied Sterilization Technologies (AST) up 13%, and a healthy debt-to-capital ratio of 21.4%, STERIS plc's stock has underperformed its industry, rising only 4.8% over the past year. This underperformance is attributed to macroeconomic headwinds, including healthcare cost containment, rising input costs, tariffs, and adverse foreign currency fluctuations, even as Zacks Consensus estimates project 9.1% EPS growth and 8.2% revenue growth for fiscal 2026.

Analysis

STERIS plc (STE) presents a dichotomous profile, characterized by strong underlying business fundamentals that are being overshadowed by macroeconomic headwinds and consequent stock underperformance. In its first quarter of fiscal 2026, the company demonstrated robust operational execution with an 8% year-over-year revenue increase in its Healthcare segment, driven by a 13% surge in service revenues and strong order growth of over 14%. The Applied Sterilization Technologies (AST) segment was even stronger, posting 13% revenue growth fueled by demand in bioprocessing and stable medical device volumes. This operational strength is complemented by a solidifying balance sheet, evidenced by a reduction in long-term debt to $1.9 billion and a decreased total debt-to-capital ratio of 21.4%. Despite these positive fundamentals and an earnings yield of 4.20% (versus the industry's -5.82%), the stock has only appreciated 4.8% over the past year, significantly lagging the industry's 17.8% and the S&P 500's 18.4% rise. This disconnect is attributed to external pressures, including healthcare cost containment, rising input costs, U.S. tariffs, and adverse foreign currency fluctuations, with nearly 30% of revenues generated outside the U.S. While forward estimates project continued growth, with fiscal 2026 consensus calling for 9.1% EPS and 8.2% revenue growth, these macro factors remain a significant drag on valuation.

Key Decisions for Investors

• Investors with existing positions may consider holding STE, given the strong operational growth in its Healthcare and AST segments and a healthy balance sheet, betting that these fundamentals will eventually outweigh the macro pressures.
• Potential investors should closely monitor trends in raw material costs, foreign exchange rates, and U.S. tariff policies, as these are the primary risks currently suppressing the stock's valuation relative to its performance.
• It is prudent to evaluate STE's significant underperformance against its industry and the broader market as an opportunity cost, especially when the report highlights better-performing peers in the same space.
• Watch for margin stabilization or improvement in upcoming earnings reports as a key catalyst, which would signal the company's ability to successfully manage inflationary and currency headwinds.